Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years

The Breast : Official Journal of the European Society of Mastology
Anna ThulinBarbro Linderholm

Abstract

Brain metastases (BM) are a feared progression of breast cancer (BC) with impact on quality of life and survival. Despite improved treatments, it is believed patients suffering from BM are increasing. To study potential changes in the number of BM, the possible links between BC subgroup and extent of BM with prognosis. To investigate the interval between primary BC/extra cranial recurrence, and diagnosis of BM in the years 1994-2014. Clinical data from 191 patients with BM diagnosed 1994-2014, was retrieved from charts. Primary tumours where re-evaluated histologically. There was an increase of BM in 5 years cohorts (1994-99 (n = 9); 2000-04 (n = 36); 2005-09 (n = 60); 2010-14 (n = 86)). We found no difference in the time interval from primary BC to BM but an insignificant increase in time from extra cranial relapse to development of BM in the time periods 1994-2004 and 2005-2014 of 15.5 and 25.0 months (p = 0.0612). Survival after BM was 7 months (95% CI 6-10) with a statistically significant difference between HER2 positive and TNBC with an inferior outcome for the latter (p = 0.018) whilst no differences were present when Luminal BC were compared with HER2 positive BC (p = 0.073). We show an increase of BM over time whilst t...Continue Reading

Citations

Jul 11, 2020·Cancers·Grace L WongHui-Wen Lo
May 29, 2021·Future Oncology·Alessandra FabiUNKNOWN AINO (Associazione Italiana Neuro-Oncologia)
Aug 6, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yaohua WeiZhiyuan Zhong

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.